Status:
COMPLETED
ACE527 Safety and Immunogenicity Study
Lead Sponsor:
TD Vaccines A/S
Collaborating Sponsors:
Pierrel Research USA, Inc.
Johns Hopkins University
Conditions:
Enterotoxigenic E. Coli (ETEC) Infection
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and immune response to ACE527.
Detailed Description
The study is a phase I, single center, double-blind, placebo-controlled dose finding clinical study to evaluate the safety, tolerability and immunogenicity of the live attenuated, oral vaccine ACE527....
Eligibility Criteria
Inclusion
- Male or female age ≥18 and ≤50 years.
- General good health, without clinically significant medical illness, physical examination findings or laboratory abnormalities, as determined by the Principal Investigator (PI) or PI in consultation with the medical monitor (MM) and sponsor.
- Negative serum pregnancy test at screening and a negative urine pregnancy test before immunization for female subjects of childbearing potential. Females of childbearing potential must not be breastfeeding and must agree to use an efficacious hormonal or barrier method of birth control during the study. Abstinence is acceptable. Female subjects unable to bear children (e.g. tubal ligation or hysterectomy) must have negative pregnancy tests.
Exclusion
- Working as a food handler, in child-care or as a healthcare worker with direct patient contact.
- Have household contacts who are \<2 years old or \>80 years old or infirm or immunocompromised (for reasons including corticosteroid therapy, HIV infection, cancer chemotherapy, or other chronic debilitating disease)
- Pregnancy, risk of pregnancy, or lactation (female subjects only).
- Abnormal stool pattern (fewer than 3 per week or more than 3 per day).
- Regular use of laxatives, antacids, or other agents to lower stomach acidity.
- Use of any medication known to affect the immune function (e.g., corticosteroids and others) within 30 days preceding the first vaccination or planned use during the active study period. (Topical and intra-articular steroids will not exclude subjects).
- Known allergy to quinolones, trimethoprim-sulfamethoxazole or penicillins.
- Symptoms consistent with Traveller's Diarrhea concurrent with travel to countries where ETEC infection in endemic (most of the developing world) within 2 years prior to vaccination.
- Received vaccination against, or ingestion of, ETEC, cholera toxin, or LT toxin within 3 years prior to vaccination.
- Use of antibiotics during the 7 days prior to vaccination and/or proton pump inhibitors, H2 blockers, or antacids within 48 hours prior to vaccination.
- History of diarrhea in the 7 days prior to vaccination (outpatient diarrhea is defined as ≥ 3 unformed loose stools in 24 hours).
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00901654
Start Date
June 1 2009
End Date
November 1 2009
Last Update
January 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Immunization Research CIR
Baltimore, Maryland, United States, 21224